# Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Source: https://onco.cc/trials/nct06726148/  
OnCo record `nct06726148` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ribociclib, Fulvestrant in small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.

## Summary

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06726148 by Novartis Pharmaceuticals, with 280 participants planned, started 2025-04-03 and due to reach its primary completion in 2028-09-25. Interventions recorded: ECI830, ribociclib, fulvestrant. Conditions listed: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06726148
- Phase: 1/2
- Setting: An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT06726148: https://clinicaltrials.gov/study/NCT06726148

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Ribociclib](https://onco.cc/drugs/ribociclib/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct06726148.json